Stifel analyst Derek Archila raised his price target on Aimmune shares to $30 from $24 after an FDA advisory panel voted 7-2 in support of Palforzia, the company's proposed treatment for peanut allergy. While he expects shares to trade up on the news, Archila said he is "not chasing the stock" and keeps a Hold rating, telling investors that the panel does not ease his concerns around the logistical challenges of launching the product, long-term compliance rates for Palforzia or "the last minute change to the second voting question granting the agency increased flexibility to potentially enforce a more onerous REMS program." His prior expectation has been for Palforzia to be approved, but he is less convicted that the treatment will achieve "aggressive" out year consensus sales forecasts, the analyst added.